Francesca Daus

Dr. Francesca Daus

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 November 2024 in Nutrition, Metabolism and Cardiovascular Diseases
Verified
Journal Article
Open access
AMALESSANDRO MALOBERTI
ALESSANDRO MALOBERTI
VCValentina Colombo
Valentina Colombo
FDFrancesca Daus
Francesca Daus
LCLorenzo De Censi
Lorenzo De Censi
MAMaurizio Giuseppe ABRIGNANI
Maurizio Giuseppe ABRIGNANI
FOFabrizio Oliva
Fabrizio Oliva
The most frequent consequence of elevated uric acid (UA) levels is the development of gout and urate kidney disease. Besides these effects, several studies have investigated the association between hyperuricemia and cardiovascular (CV) disease. High serum UA has been identified as an important determinant of all-cause and CV mortality and CV events (acute and chronic coronary syndrome, stroke and peripheral artery disease). Despite the high number of publications on this topic, there are two questions that are still unanswered: do we need a specific CV cut-off of serum UA to better refine the CV risk? Is urate lowering treatment (ULT) able to reduce CV risk in asymptomatic patients? In this review, we will focus on these two points. Although no doubt exists that the relationship between CV events starts at lower levels than the actually used cut-off, different papers found dissimilar cut-offs. Furthermore, heterogeneity is present depending on the specific CV events evaluated and none of the found cut-off have been tested in external populations (in order to confirm its discriminatory capacity). Furthermore, only few randomized clinical trials on the role of hypouricemic agents in reducing the CV risk have been published giving heterogeneous results. The last published one (ALL-HEART) has strong limitations, that we will deeply discuss. A definitive answer to the two questions is impossible with the actually published paper but, over identifying current gaps in knowledge we try to individuate how they can be overruled.

RSRoberto Spoladore
Roberto Spoladore
GPGiuseppe Pinto
Giuseppe Pinto
FDFrancesca Daus
Francesca Daus
SPSara Pezzini
Sara Pezzini
DKDamianos Kolios
Damianos Kolios
GFGabriele Fragasso
Gabriele Fragasso
In dilated cardiomyopathy (DCM), where the heart muscle becomes stretched and thin, heart failure (HF) occurs, and the cardiomyocytes suffer from an energetic inefficiency caused by an abnormal cardiac metabolism. Although underappreciated as a potential therapeutic target, the optimal metabolic milieu of a failing heart is still largely unknown and subject to debate. Because glucose naturally has a lower P/O ratio (the ATP yield per oxygen atom), the previous studies using this strategy to increase glucose oxidation have produced some intriguing findings. In reality, the vast majority of small-scale pilot trials using trimetazidine, ranolazine, perhexiline, and etomoxir have demonstrated enhanced left ventricular (LV) function and, in some circumstances, myocardial energetics in chronic ischemic and non-ischemic HF with a reduced ejection fraction (EF). However, for unidentified reasons, none of these drugs has ever been tested in a clinical trial of sufficient size. Other pilot studies came to the conclusion that because the heart in severe dilated cardiomyopathy appears to be metabolically flexible and not limited by oxygen, the current rationale for increasing glucose oxidation as a therapeutic target is contradicted and increasing fatty acid oxidation is supported. As a result, treating metabolic dysfunction in HF may benefit from raising ketone body levels. Interestingly, treatment with sodium-glucose cotransporter-2 inhibitors (SGLT2i) improves cardiac function and outcomes in HF patients with or without type 2 diabetes mellitus (T2DM) through a variety of pleiotropic effects, such as elevated ketone body levels. The improvement in overall cardiac function seen in patients receiving SGLT2i could be explained by this increase, which appears to be a reflection of an adaptive process that optimizes cardiac energy metabolism. This review aims to identify the best metabolic therapeutic approach for DCM patients, to examine the drugs that directly affect cardiac metabolism, and to outline all the potential ancillary metabolic effects of the guideline-directed medical therapy. In addition, a special focus is placed on SGLT2i, which were first studied and prescribed to diabetic patients before being successfully incorporated into the pharmacological arsenal for HF patients.

14 January 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
POPaolo Ossola
Paolo Ossola
SGSimone Ghidini
Simone Ghidini
EGElena Gualini
Elena Gualini
FDFrancesca Daus
Francesca Daus
FPFrancesco Politi
Francesco Politi
CGCristina Giannattasio
Cristina Giannattasio
Aortic stenosis (AS) is the most prevalent valvular heart disease in Western countries and it is especially associated with older age. With its progressive course, AS leads to ventricular hypertrophy, impaired diastolic and systolic function, and symptomatic deterioration. The natural history of AS is closely linked to the extent of myocardial and extracardiac damage in association with the patients comorbidities. Diagnosis relies primarily on transthoracic echocardiography, which assesses valve morphology, quantifies stenosis severity, and evaluates cardiac remodeling. However, discordant grading is frequent, necessitating advanced imaging to clarify the severity and the mechanism of the stenosis and stratify risk. Treatment is predominantly interventional, as no medical therapy is able to stop disease progression. Surgical aortic valve replacement (SAVR) and transcatheter aortic valve replacement (TAVR) are the two treatment options. Special clinical scenarios—such as cardiogenic shock or concomitant cardiac amyloidosis—pose additional diagnostic and therapeutic challenges and require individualized, multidisciplinary management. Overall, contemporary AS care increasingly integrates multimodality imaging, refined risk stratification, and tailored interventional strategies to optimize outcomes.

SPSara Pezzini
Sara Pezzini
FDFrancesca Daus
Francesca Daus
GGGiorgia Galli
Giorgia Galli
AFAndrea Farina
Andrea Farina
GFGabriele Fragasso
Gabriele Fragasso
RSRoberto Spoladore
Roberto Spoladore
With its high spatial resolution and tissue contrast, cardiac magnetic resonance (CMR) is an extremely flexible imaging technique that enables a thorough morphological and functional evaluation of the heart and vascular system. From diagnosis to treatment planning and risk assessment, CMR is being utilized more and more in the evaluation of patients with heart failure (HF). CMR offers a variety of techniques for characterizing myocardial tissue, aiding in identifying the cause of HF, as well as whole-heart cine imaging for precise measurement of biventricular dimensions and function. The aim of this review is to the describe the role of CMR in chronic heart failure, in particular for diagnostic workups, differential diagnosis, and information on how CMR influences treatment planning choices.